Moyamoya disease 1

A hereditary autosomal recessive form of Moyamoya disease. Susceptibility has been mapped to chromosome 3. OMIM: 252350

Also Known As:

MYMY1; Spontaneous occlusion of the circle of Willis

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Disease Context: Research Results

Related Diseases

1.	Moyamoya Disease (Moya-Moya Disease)
2.	Central Nervous System Vascular Malformations (Dural Arteriovenous Fistula)
3.	Stroke (Strokes)
4.	Hemorrhage
5.	Headache (Headaches)

Experts

1.	Bernucci, Claudio: 1 article (05/2018)
2.	Brembilla, Carlo: 1 article (05/2018)
3.	Colleoni, Maria Luisa: 1 article (05/2018)
4.	Conti, Luciano: 1 article (05/2018)
5.	Galliani, Silvia: 1 article (05/2018)
6.	Gritti, Paolo: 1 article (05/2018)
7.	Lanterna, Luigi A: 1 article (05/2018)
8.	Zangari, Rosalia: 1 article (05/2018)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Moyamoya disease 1:

1.	ThrombomodulinIBA 05/01/1993 - "Expression of thrombomodulin in patients with spontaneous occlusion of the circle of Willis." 05/01/1993 - "We examined the expression of thrombomodulin, a recently isolated anticoagulant protein, in endothelial cells from patients with spontaneous occlusion of the circle of Willis (cerebrovascular moyamoya disease) to determine whether lack of the expression of thrombomodulin might lead to the thrombogenicity in patients with this disease. "
2.	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 10/01/1993 - "The cerebrospinal fluid in patients with moyamoya disease (spontaneous occlusion of the circle of Willis) contains high level of basic fibroblast growth factor."
3.	Proteins (Proteins, Gene)FDA Link 05/01/1993 - "We examined the expression of thrombomodulin, a recently isolated anticoagulant protein, in endothelial cells from patients with spontaneous occlusion of the circle of Willis (cerebrovascular moyamoya disease) to determine whether lack of the expression of thrombomodulin might lead to the thrombogenicity in patients with this disease. "
4.	AutoantibodiesIBA 05/01/2018 - "We studied the effect of gender, age, type of moyamoya (uMM versus MMD), and thyroid autoantibodies on the clinical presentation, dichotomized into aggressive (hemorrhage, major stroke, or frequent transient ischemic attack [TIA]) and nonaggressive presentation (headache, rare TIAs, and incidental diagnosis) according to the criteria of the Research Committee on Spontaneous Occlusion of the Circle of Willis. "
5.	AnticoagulantsIBA 05/01/1993 - "We examined the expression of thrombomodulin, a recently isolated anticoagulant protein, in endothelial cells from patients with spontaneous occlusion of the circle of Willis (cerebrovascular moyamoya disease) to determine whether lack of the expression of thrombomodulin might lead to the thrombogenicity in patients with this disease. "

Therapies and Procedures

1.	Microvascular Decompression Surgery 03/01/2023 - "Procedures included 12 intracranial aneurysm clippings, 6 brain and 1 spinal arteriovenous malformation resections, 2 cranial dural arteriovenous fistula obliterations, 3 carotid endarterectomies, two extracranial-intracranial direct bypasses, two encephaloduroangiosynostosis for Moyamoya disease, 1 biopsy of the superficial temporal artery, 2 microvascular decompressions, 2 cavernoma resections, 1 combined intracranial aneurysm clipping and encephaloduroangiosynostosis for Moyamoya disease, and 1 percutaneous feeder catheterization for arteriovenous malformation embolization. "
2.	Carotid Endarterectomy 03/01/2023 - "Procedures included 12 intracranial aneurysm clippings, 6 brain and 1 spinal arteriovenous malformation resections, 2 cranial dural arteriovenous fistula obliterations, 3 carotid endarterectomies, two extracranial-intracranial direct bypasses, two encephaloduroangiosynostosis for Moyamoya disease, 1 biopsy of the superficial temporal artery, 2 microvascular decompressions, 2 cavernoma resections, 1 combined intracranial aneurysm clipping and encephaloduroangiosynostosis for Moyamoya disease, and 1 percutaneous feeder catheterization for arteriovenous malformation embolization. "